Akari Therapeutics (AKTX) News Today $0.84 -0.01 (-1.16%) Closing price 09/9/2025 03:49 PM EasternExtended Trading$0.84 -0.01 (-0.61%) As of 09/9/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock AKTX Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period HC Wainwright Reiterates Buy Rating for Akari Therapeutics (NASDAQ:AKTX)2 hours ago | americanbankingnews.comAkari Therapeutics PLC (NASDAQ:AKTX) Short Interest UpdateSeptember 8 at 3:23 AM | americanbankingnews.comAkari Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 5, 2025 | globenewswire.comAkari Therapeutics (NASDAQ:AKTX) Shares Cross Below 200-Day Moving Average - Time to Sell?September 4, 2025 | americanbankingnews.comAkari Therapeutics to Participate in the Virtual Investor Closing Bell SeriesSeptember 3, 2025 | globenewswire.comAkari Therapeutics to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTechAugust 14, 2025 | globenewswire.comAkari Therapeutics Releases Virtual Investor “What This Means” SegmentJuly 29, 2025 | globenewswire.comAkari Therapeutics Continues Key Research on its Novel Antibody Drug Conjugate Payload PH1 to Further Demonstrate its Unique Ability to Target Cancers Fueled by Oncogenic DriversJuly 23, 2025 | globenewswire.comAkari Therapeutics Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand ConferenceJuly 23, 2025 | finance.yahoo.comAkari Therapeutics Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand ConferenceJuly 22, 2025 | globenewswire.comMaxim Group Initiates Coverage of Akari Therapeutics, Plc - Depositary Receipt () (AKTX) with Buy RecommendationJuly 20, 2025 | msn.comAkari Therapeutics initiated with a Buy at MaximJuly 19, 2025 | msn.comPVL: Akari completes Set 3 comeback vs. Capital1 to end group stage on high noteJuly 16, 2025 | msn.comAkari Therapeutics Insiders Added US$1.79m Of Stock To Their HoldingsJuly 16, 2025 | finance.yahoo.comAlba charges up Akari in PVLJuly 9, 2025 | msn.comAkari Therapeutics shareholders approve equity plan increase and director electionsJuly 3, 2025 | uk.investing.comAkari Therapeutics, Plc (AKTX) - Yahoo FinanceJuly 1, 2025 | uk.finance.yahoo.comAkari Therapeutics Plc (AKTX) Stock ForecastsJune 26, 2025 | ca.finance.yahoo.comAkari Therapeutics Releases Virtual Investor “What This Means” Segment Highlighting its Recently Granted India PatentJune 25, 2025 | globenewswire.comAkari Therapeutics PLC (NASDAQ:AKTX) CEO Abizer Gaslightwala Purchases 10,000 SharesJune 25, 2025 | insidertrades.comAkari Therapeutics Secures Patent for PH1 Cancer Therapy Amid Rising Cancer Rates in IndiaJune 20, 2025 | nasdaq.comAkari Therapeutics Plc: Akari Therapeutics Bolsters Global IP Estate for its Novel Antibody Drug Conjugate (ADC) Immuno-Oncology Payload, PH1, with Recent Granting of Patent ...June 19, 2025 | finanznachrichten.deAkari Therapeutics Bolsters Global IP Estate for its Novel Antibody Drug Conjugate (ADC) Immuno-Oncology Payload, PH1, with Recent Granting of Patent Protection Across IndiaJune 18, 2025 | globenewswire.comAkari Therapeutics Releases “Meet the Team” Video Featuring Recently Appointed Mark F. Kubik, Head of Business Development – OncologyMay 29, 2025 | globenewswire.comAkari Therapeutics Appoints New Head of Business Development - Oncology and Advances Novel Antibody Drug Conjugates for Cancer TreatmentMay 17, 2025 | nasdaq.comAkari Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 15, 2025 | globenewswire.comAkari Therapeutics Appoints Mark F. Kubik as Head of Business Development - Oncology to Advance ADC PlatformMay 3, 2025 | nasdaq.comAkari Therapeutics appoints new head of oncology businessMay 3, 2025 | uk.investing.comAkari Therapeutics Appoints Mark F. Kubik as Head of Business Development - OncologyMay 1, 2025 | globenewswire.comAkari Therapeutics Releases Welcome Video from Newly Appointed Chief Executive Officer, Abizer GaslightwalaApril 22, 2025 | globenewswire.comAkari Therapeutics reports FY24 EPS 0c vs 0c last yearApril 18, 2025 | markets.businessinsider.comAkari Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate UpdateApril 16, 2025 | markets.businessinsider.comAkari Therapeutics names new CEO to drive cancer drug innovationMarch 22, 2025 | uk.investing.comThis Micro Cap Continues This Week's Dominance Amid New CEO AppointmentMarch 21, 2025 | msn.comAkari Therapeutics appoints Gaslightwala as CEOMarch 21, 2025 | markets.businessinsider.comAkari Therapeutics Plc: Akari Therapeutics Appoints Biotechnology Industry Leader, Abizer Gaslightwala, as President and Chief Executive OfficerMarch 20, 2025 | finanznachrichten.deAkari Therapeutics Appoints Biotechnology Industry Leader, Abizer Gaslightwala, as President and Chief Executive OfficerMarch 20, 2025 | globenewswire.comAkari Therapeutics announces $7.6M private placement offeringMarch 3, 2025 | markets.businessinsider.comAkari Therapeutics Announces $7.6 Million Private Placement Offering Led by Existing Shareholders and Insiders Priced at the Market Under Nasdaq RulesMarch 3, 2025 | globenewswire.comEuropean Equities Traded in the US as American Depositary Receipts Edge Higher in Friday TradingFebruary 21, 2025 | msn.comVirtual Investor "Top 5 for '25" Conference Hosted by JTC Now Available On-DemandFebruary 19, 2025 | markets.businessinsider.comAkari Therapeutics Participates in the Virtual Investor “Top 5 for ‘25” On-Demand ConferenceFebruary 19, 2025 | globenewswire.comAkari Therapeutics Joins Webull Corporate Connect Service PlatformFebruary 3, 2025 | globenewswire.comAkari Therapeutics Announces Key Leadership AppointmentsDecember 18, 2024 | globenewswire.comAkari Therapeutics Appoints Torsten Hombeck as CFODecember 16, 2024 | markets.businessinsider.comAkari Therapeutics Appoints Torsten Hombeck, Ph.D. as Chief Financial OfficerDecember 16, 2024 | globenewswire.comAkari Therapeutics Announces Leadership RestructuringDecember 14, 2024 | markets.businessinsider.comEuropean Equities Traded in the US as American Depositary Edge Lower in Thursday TradingDecember 12, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Decline in Wednesday TradingNovember 20, 2024 | msn.comAkari Therapeutics regains full Nasdaq comlianceNovember 20, 2024 | markets.businessinsider.com Get Akari Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AKTX Media Mentions By Week AKTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AKTX News Sentiment▼0.290.75▲Average Medical News Sentiment AKTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AKTX Articles This Week▼51▲AKTX Articles Average Week Get the Latest News and Ratings for AKTX and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Akari Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Elutia News Today XBiotech News Today Anixa Biosciences News Today Virios Therapeutics News Today Celularity News Today Ovid Therapeutics News Today Cardiol Therapeutics News Today Oramed Pharmaceuticals News Today Vaxart News Today CervoMed News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AKTX) was last updated on 9/10/2025 by MarketBeat.com Staff From Our Partners“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | SponsoredUnlock Friday's Full Potential: Two Simple Sentences that put profits in investors’ pocketsMost traders stick to the same routine each week. But a little-known market strategy has quietly delivered a 9...Eagle Publishing | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredWall Street legend: “Put $1,000 in this AI stock”A massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akari Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Akari Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AKTX Stock Alerts